Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Correlation of New Method for Measuring Plasma Myeloperoxidase with Clinical Behavior in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Adam Abdool, Xiugiang Wang, Iman Jilani, Ph.D., Weidong Zhou, M.D., Hagop Kantargian, M.D., Elihu Estey, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 4321.

https://doi.org/10.1182/blood.V110.11.4321.4321

Published: 2007

Journal Articles

Molecular Basis Explanation of Imatinib Resistance of Bcr-Abl Due to T315I and P-Loop Mutations from Molecular Dynamics Simulations.

Tai-Sung Lee, Steven Potts, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2917.

https://doi.org/10.1182/blood.V110.11.2917.2917

Published: 2007

Journal Articles

Proteasome Chymotrypsin-Like Activity in Plasma Is a Major Predictor of Outcome in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Normal Karyotype.

Wanlong Ma, Iman Jilani, Ph.D., Benjamin Bekele, Hagop Kantarjian, M.D., Amber Donahue, Ph.D., Xi Zhang, Zhong Zhang, M.D., Susan O’Brien, M.D., Elihu Estey, M.D., Zeev Estrov, M.D., Jorge Cortes, M.D., Michael Keating, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2837.

https://doi.org/10.1182/blood.V110.11.2837.2837

Published: 2007

Journal Articles

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib.

Richard Tseng, PhD, Chen-Hsiung Yeh, Ph.D., Iman Jilani, Ph.D., Zhong Zhang, M.D., Hagop Kantarjian, M.D., Jorge Cortes, M.D., Susan O’Brien, M.D., Francis Giles, M.D., Alison Hannah, Ph.D., Zeev Estrov, M.D., Michael Keating, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2922.

https://doi.org/10.1182/blood.V110.11.2922.2922

Published: 2007

Journal Articles

Detection of Nucleophosmin Gene Mutations in Plasma from Patients with Acute Myeloid Leukemia: Clinical Significance and Implications.

Wanlong Ma, Xi Zhang, Iman Jilani, Ph.D., Farhad Ravandi, Elihu Estey, M.D., Hagop Kantarjian, M.D., Francis Giles, M.D., Mohammad Sheikholeslami, M.D., Michael Keating, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2855.

https://doi.org/10.1182/blood.V110.11.2855.2855

Published: 2007

Journal Articles

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Wanlong Ma, Xi Zhang, Iman Jilani, Ph.D., Zhong Zhang, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D., Francis Giles, M.D., Susan O’Brien, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 2554.

https://doi.org/10.1182/blood.V110.11.2554.2554

Published: 2007

Journal Articles

Higher Sensitivity and Detection of Homozygous/Hemizygous State of JAK2 Mutation Using Plasma.

Wanlong Ma, Xi Zhang, Weimin Sun, Ph.D, Joyce Schwartz, M.D., Arlene Buller, Ph.D., Iman Jilani, Ph.D., Hagop Kantarjian, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 4663.

https://doi.org/10.1182/blood.V110.11.4663.4663

Published: 2007

Journal Articles

Activity of Circulating Proteasomes Correlates with Clinical Behavior in Patients with Chronic Myeloid Leukemia.

Wanlong Ma, Hagop Kantarjian, M.D., Amber Donahue, Ph.D., Xi Zhang, Susan O’Brien, M.D., Iman Jilani, Ph.D., Elihu Estey, M.D., Zeev Estrov, M.D., Jorge Cortes, M.D., Michael Keating, M.D., Francis Giles, M.D., Maher Albitar, M.D.

Blood (2007) 110 (11): 4546.

https://doi.org/10.1182/blood.V110.11.4546.4546

Published: 2007

Journal Articles

Translational In Vivo and In Vitro Studies in Patients (pts) with Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML) and Myeloproliferative Disease (MPD) Treated with MK-0457 (MK), a Novel Aurora Kinase, Flt3, JAK2, and Bcr-Abl Inhibitor.

Raoul Tibes, MD, Francis Giles, M.D., Teresa McQueen, Donald A. Bergstrom, M.D., Ph.D., Steven J. Freedman, M.D., Ph.D., Michael Andreeff, M.D., Ph.D.

Blood (2006) 108 (11): 1362.

https://doi.org/10.1182/blood.V108.11.1362.1362

Published: 2006

Journal Articles

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Ehab Atallah, MD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Sherry Pierce, R.N., Elihu Estey, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.,; PhD.

Blood (2006) 108 (11): 2612.

https://doi.org/10.1182/blood.V108.11.2612.2612

Published: 2006

Journal Articles

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Elias Jabbour, MD, Hagop M. Kantarjian, M.D., Jorge Cortes, M.D., William G. Wierda, M.D., Ph.D., Alessandra Ferrajoli, M.D., Stefan Faderl, M.D., Susan O’Brien, M.D., Farhad Ravandi-Kashani, M.D., Srdan Verstovsek, M.D., Ph.D., Guillermo Garcia-Manero, M.D., Jan Davisson, BS, ADN, Francis Giles, M.D., Jianqin Shan, Ph.D., Jean-Pierre Issa, M.D.

Blood (2006) 108 (11): 2652.

https://doi.org/10.1182/blood.V108.11.2652.2652

Published: 2006

Journal Articles

Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.

Constantine S. Tam, MD, Francis Giles, M.D., Jorge Cortes, M.D., Guillermo Garcia-Manero, M.D., Elihu Estey, M.D., Hagop Kantarjian, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 2705.

https://doi.org/10.1182/blood.V108.11.2705.2705

Published: 2006

Journal Articles

A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF).

Alfonso Quintas-Cardama, MD, Hagop Kantarjian, M.D., Guillermo Garcia-Manero, M.D., Deborah Thomas, M.D., STeven Kornblau, M.D., Elihu Estey, M.D., Marilyn Nemri, R.N., Jorge Cortes, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.;PhD

Blood (2006) 108 (11): 2706.

https://doi.org/10.1182/blood.V108.11.2706.2706

Published: 2006

Journal Articles

Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age ≥ 60 with Newly-Diagnosed AML.

Elihu H. Estey, MD, Guillermo Garcia-Manero, M.D., Francis Giles, M.D., Hagop M. Kantarjian, M.D.

Blood (2006) 108 (11): 1965.

https://doi.org/10.1182/blood.V108.11.1965.1965

Published: 2006

Journal Articles

Clinical Significance of Free Circulating CD4 and CD8 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Adam Abdool, Francis Giles, M.D., Menna Hodge, Susan O’Brien, M.D., Michael Keating, M.D., Iman Jilani, PhD, Hagop Kantarjian, M.D., Elihu Estey, M.D., Maher Albitar, M.D.

Blood (2006) 108 (11): 1889.

https://doi.org/10.1182/blood.V108.11.1889.1889

Published: 2006

Journal Articles

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Elias Jabbour, MD, Hagop Kantarjian, M.D., Charles A. Koller, M.D., Stefan Faderl, M.D., Alessandra Ferrajoli, M.D., Mary Ann Richie, R.N., Guillermo Garcia-Manero, M.D., Jorge Cortes, M.D., Zeev Estrov, M.D., Farhad Ravandi-Kashani, M.D., Francis Giles, M.D., Srdan Verstovsek, M.D.

Blood (2006) 108 (11): 3636.

https://doi.org/10.1182/blood.V108.11.3636.3636

Published: 2006

Journal Articles

Clinical Significance of Free Circulating CD34 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Menna Hodge, Francis Giles, M.D., Adam Abdool, M.D., Susan O’Brien, M.D., Michael Keating, M.D., Iman Jilani, PhD, Zeev Estrov, M.D., Elihu Estey, M.D., Hagop Kantarjian, M.D., Maher Albitar, M.D.

Blood (2006) 108 (11): 4495.

https://doi.org/10.1182/blood.V108.11.4495.4495

Published: 2006

Journal Articles

Variations in Proteasome Enzymatic Activities in Plasma of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome and Their Value in Predicting Clinical Behavior.

Wanlong Ma, Francis Giles, M.D., Susan O’Brien, M.D., Iman Jilani, PhD, Xi Zhang, Zeev Estrov, M.D., Elihu Estey, M.D., Alessandra Ferrajoli, M.D., Michael Keating, M.D., Maher Albitar, M.D.

Blood (2006) 108 (11): 4497.

https://doi.org/10.1182/blood.V108.11.4497.4497

Published: 2006

Journal Articles

Clinical Significance of Free Circulating CD33 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Menna Hodge, Francis Giles, M.D., Adam Abdool, Susan O’Brien, M.D., Michael Keating, M.D., Iman Jilani, PhD, Zeev Estrov, M.D., Elihu Estey, M.D., Hagop Kantarjian, M.D., Maher Albitar, M.D.

Blood (2006) 108 (11): 4502.

https://doi.org/10.1182/blood.V108.11.4502.4502

Published: 2006

Journal Articles

Comparison of Survival Times after Administration of Tipifarnib or Ara-C-Containing Therapy, to Older Patients with Newly-Diagnosed Acute Myeloid Leukemia.

Elihu H. Estey, MD, Peter F. Thall, Ph.D., X.-M. Wang, M.S., Francis Giles, M.D., Judith E. Karp, M.D.

Blood (2006) 108 (11): 4552.

https://doi.org/10.1182/blood.V108.11.4552.4552

Published: 2006

NARROW

Correlation of New Method for Measuring Plasma Myeloperoxidase with Clinical Behavior in Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Molecular Basis Explanation of Imatinib Resistance of Bcr-Abl Due to T315I and P-Loop Mutations from Molecular Dynamics Simulations.

Proteasome Chymotrypsin-Like Activity in Plasma Is a Major Predictor of Outcome in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Normal Karyotype.

High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib.

Detection of Nucleophosmin Gene Mutations in Plasma from Patients with Acute Myeloid Leukemia: Clinical Significance and Implications.

Overexpression of JAK2 mRNA in Chronic Myeloproliferative Disease and Its Implication on Mutation Testing and Biology of Disease.

Higher Sensitivity and Detection of Homozygous/Hemizygous State of JAK2 Mutation Using Plasma.

Activity of Circulating Proteasomes Correlates with Clinical Behavior in Patients with Chronic Myeloid Leukemia.

Translational In Vivo and In Vitro Studies in Patients (pts) with Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML) and Myeloproliferative Disease (MPD) Treated with MK-0457 (MK), a Novel Aurora Kinase, Flt3, JAK2, and Bcr-Abl Inhibitor.

Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.

Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).

Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.

A Phase II Study of Azacitidine (Vidaza™) for Patients with Myelofibrosis (MF).

Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age ≥ 60 with Newly-Diagnosed AML.

Clinical Significance of Free Circulating CD4 and CD8 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.

Clinical Significance of Free Circulating CD34 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Variations in Proteasome Enzymatic Activities in Plasma of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome and Their Value in Predicting Clinical Behavior.

Clinical Significance of Free Circulating CD33 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

Comparison of Survival Times after Administration of Tipifarnib or Ara-C-Containing Therapy, to Older Patients with Newly-Diagnosed Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only